KALA insider sale: 20,806 shares at $0.83; 28,878 RSUs included

Q: What did KALA (KALA) disclose in this Form 4?

The Chief Business Officer sold 20,806 shares on 10/22/2025 at a $0.83 weighted average price.

Q: What price range were the KALA shares sold at?

Sales occurred between $0.82 and $0.84 , inclusive, with a weighted average of $0.83 .

Q: How many KALA shares does the insider own after the transaction?

The officer beneficially owns 41,760 shares directly after the reported sale.

Q: Does the remaining KALA ownership include equity awards?

Yes. The balance includes 28,878 unvested RSUs .

Q: What is the insider’s role at KALA BIO?

The reporting person is an officer, serving as Chief Business Officer .

Q: Was this a single trade or multiple trades?

Multiple trades were executed within the $0.82–$0.84 range; the reported price is a weighted average.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

KALA BIO (KALA) reported an insider transaction by its Chief Business Officer. On 10/22/2025, the officer sold 20,806 shares of common stock at a $0.83 weighted average price, with trades ranging from $0.82 to $0.84. Following the sale, the officer beneficially owned 41,760 shares directly.

The reported balance includes 28,878 unvested RSUs, which are awards that may settle in shares as they vest. The filing lists direct ownership and does not indicate joint or group filing.

Insider Trade Summary

Net Seller: 20,806 shares ($17,269)

Net Sell 1 txn

Insider Kharabi Darius

Role CHIEF BUSINESS OFFICER

Sold 20,806 shs ($17K)

Type	Security	Shares	Price	Value
Sale	Common Stock	20,806	$0.83	$17K

Holdings After Transaction: Common Stock — 41,760 shares (Direct)

Footnotes (1)

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Includes 28,878 unvested RSUs.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/24/2025 - 08:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kharabi Darius

(Last)

(First)

(Middle)

C/O KALA BIO, INC.

1167 MASSACHUSETTS AVENUE

(Street)

ARLINGTON

02476

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF BUSINESS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/22/2025		S		20,806	D	$0.83⁽¹⁾	41,760⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

2. Includes 28,878 unvested RSUs.

	/s/ Mary Reumuth, Attorney-in-Fact	10/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did KALA (KALA) disclose in this Form 4?

The Chief Business Officer sold 20,806 shares on 10/22/2025 at a $0.83 weighted average price.

What price range were the KALA shares sold at?

Sales occurred between $0.82 and $0.84, inclusive, with a weighted average of $0.83.

How many KALA shares does the insider own after the transaction?

The officer beneficially owns 41,760 shares directly after the reported sale.

Does the remaining KALA ownership include equity awards?

Yes. The balance includes 28,878 unvested RSUs.

What is the insider’s role at KALA BIO?

The reporting person is an officer, serving as Chief Business Officer.

Was this a single trade or multiple trades?

Multiple trades were executed within the $0.82–$0.84 range; the reported price is a weighted average.